I MINA'TRENTAI UNU NA LIHESLATURAN GUÅHAN
2011 (FIRST) Regular Session

CERTIFICATION OF PASSAGE OF AN ACT TO *I MAGA'LAHEN GUÅHAN*

This is to certify that **Substitute Bill No. 216-31 (COR), "AN ACT TO *AMEND* ITEMS (C), (D) AND (E), AND TO *ADD* A NEW ITEM (F) TO APPENDIX A; TO *AMEND* ITEMS (A)(1), (B), (C), (E) AND (F) OF APPENDIX B; TO *AMEND* ITEMS (B), (C), (D) AND (E), AND TO *ADD* A NEW ITEM (F) TO APPENDIX C; TO *AMEND* ITEMS (B), (C) AND (D) OF APPENDIX D; TO *AMEND* ITEM (A), AND TO *ADD* A NEW ITEM (D) TO APPENDIX E; AND TO *ADD* A NEW §67.301(f) TO ARTICLE 3, ALL OF CHAPTER 67 OF TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT BASED ON THE U.S. DRUG ENFORCEMENT ADMINISTRATION SCHEDULE LISTING,"** was on the 19th day of September, 2011, duly and regularly passed.

Judith T. Won Pat, Ed.D.
Speaker

Attested:

Tina Rose Muña Barnes
Legislative Secretary

This Act was received by *I Maga'lahen Guåhan* this 20th day of Sept, 2011, at 4:10 o'clock P.M.

Assistant Staff Officer
Maga'lahi's Office

APPROVED:

EDWARD J.B. CALVO
I Maga'lahen Guåhan

Date: _____
Public Law No. _____

I MINA'TRENTAI UNU NA LIHESLATURAN GUÅHAN
2011 (FIRST) Regular Session

Bill No. 216-31 (COR)
As substituted by the Committee on Public Safety,
Law Enforcement and Judiciary.

Introduced by:

B. J.F. Cruz
Adolpho B. Palacios, Sr.
T. C. Ada
V. Anthony Ada
F. F. Blas, Jr.
Chris M. Dueñas
Judith P. Guthertz, DPA
Sam Mabini, Ph.D.
T. R. Muña Barnes
v. c. pangelinan
Dennis G. Rodriguez, Jr.
R. J. Respicio
M. Silva Taijeron
Aline A.Yamashita, Ph.D.
Judith T. Won Pat, Ed.D.

AN ACT TO *AMEND* ITEMS (C), (D) AND (E), AND TO *ADD* A NEW ITEM (F) TO APPENDIX A; TO *AMEND* ITEMS (A)(1), (B), (C), (E) AND (F) OF APPENDIX B; TO *AMEND* ITEMS (B), (C), (D) AND (E), AND TO *ADD* A NEW ITEM (F) TO APPENDIX C; TO *AMEND* ITEMS (B), (C) AND (D) OF APPENDIX D; TO *AMEND* ITEM (A), AND TO *ADD* A NEW ITEM (D) TO APPENDIX E; AND TO *ADD* A NEW §67.301(f) TO ARTICLE 3, ALL OF CHAPTER 67 OF TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT BASED ON THE U.S. DRUG ENFORCEMENT ADMINISTRATION SCHEDULE LISTING.

BE IT ENACTED BY THE PEOPLE OF GUAM:

Section 1. Item (C) of Appendix A of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(C) Material, compound, mixture or preparation containing any quantity of the following hallucinogenic substances, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(1) Alpha-ethyltryptamine (other names: etryptamine; Monase; alpha-ethyl-lH-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET);

(2) 4-bromo-2,5-dimethoxy-amphetamine (other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA);

(3) 4-bromo-2,5-dimethoxyphenethylamine (other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus);

(4) 2,5-dimethoxyamphetamine (other names: 2,5-dimethoxyalpha-methylphenethylamine; 2,5-DMA);

(5) 2,5-dimethoxy-4-ethylamphet-amine (other name: DOET);

(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);

(7) 4-methoxyamphetamine (other names: 4-methoxy-alphamethylphenethylamine; paramethoxyamphetamine, PMA);

(8) 5-methoxy-3,4-methylenedioxy-amphetamine;

(9) 4-methyl-2,5-dimethoxy-amphetamine (other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP);

(10) 3,4-methylenedioxy amphetamine;

(11) 3,4-methylenedioxymethamphetamine (MDMA);

(12) 3,4-methylenedioxy-N-ethylamphetamine (other names: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);

(13) N-hydroxy-3,4-methylenedioxyamphetamine (other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);

(14) 3, 4, 5-trimethoxy amphetamine;

(15) 5-methoxy-N,N-dimethyltryptamine (other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT;

(16) Alpha-methyltryptamine (other name: AMT);

(17) bufotenine (other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine);

(18) diethyltryptamine (other names: N,N-Diethyltryptamine; DET);

(19) dimethyltryptamine (other name: DMT);

(20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);

(21) ibogaine (other names: (7-Ethyl-6,6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; tabernanthe iboga);

(22) lysergic acid diethylamide;

(23) marihuana;

(24) mescaline;

(25) parahexyl (other names: 3-Hexyl-l-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl);

(26) peyote (all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, its seeds, any extract from any part of the plant, and every compound manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts);

(27) N-ethyl-3-piperidyl benzilate;

(28) N-methyl-3-piperidyl benzilate;

(29) psilocybin;

(30) psilocyn;

(31) tetrahydrocannabinols (Meaning tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis* (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:

-1 cis or trans tetrahydrocannabinol, and their optical isomers;

-6 cis or trans tetrahydrocannabinol, and their optical isomers; and

-3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numeric designation of atomic positions covered.);

(32) ethylamine analog of phencyclidine (other names: N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine; N-(l-phenylcyclohexyl) ethylamine; cyclohexamine; PCE);

(33) pyrrolidine analog of phencyclidine (other names: 1- (l-phenylcyclohexyl)–pyrrolidine; PCPy; PHP);

(34) thiophene analog of phencyclidine (other names: 1-[l-(2-thienyl)-cyclohexyl]-piperidine; 2-thienylanalog of phencyclidine; TPCP; TCP); and

(35) TCPy (other name: 1-[l-(2-thienyl)cyclohexyl] pyrrolidine."

Section 2. Item (D) of Appendix A of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(D) Material, compound, mixture or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers and salts of isomers of them that are theoretically possible within the specific chemical designation:

(1) gamma-hydroxybutyric acid (other names: include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

(2) mecloqualone; and

(3) methaqualone."

Section 3. Item (E) of Appendix A of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(E) Material, compound, mixture or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:

(1) Aminorex (other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine);

(2) N-Benzylpiperazine (other names: BZP, 1-benzylpiperazine);

(3) Cathinone (other names: 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrone);

(4) Fenethylline;

(5) Methcathinone (other names: 2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-l-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432), its salts, optical isomers and salts of optical isomers);

(6) (+/-)cis-4-methylaminorex (other name: (+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

(7) N-ethylamphetamine; and

(8) N,N-dimethylamphetamine (other names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine)."

Section 4. A new Item (F) is hereby *added* to Appendix A of Chapter 67, Title 9, Guam Code Annotated, to read:

"(F) *Temporary listing of substances subject to emergency scheduling.* Any material, compound, mixture or preparation which contains any quantity of the following substances:

(1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-ydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: CP-47,497);

(2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: cannabicyclohexanol and CP-47,497 C8 homologue);

(3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: JWH- 073);

(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: JWH-200); and

(5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: JWH- 018 and AM678)."

Section 5. Item (A) (1) of Appendix B of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(A) Any of the following substances, however manufactured:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:

(A) raw opium;

(B) opium extracts;

(C) opium fluid;

(D) powdered opium;

(E) granulated opium;

(F) tincture of opium;

(G) codeine;

(H) ethylmorphine;

(I) etorphine hydrochloride;

(J) hydrocodone;

(K) hydromorphone;

(L) metopon;

(M) morphine;

(N) oxycodone;

(O) oxymorphone;

(P) thebaine;

(Q) dihydroetorphine; and

(R) oripavine."

Section 6. Item (B) of Appendix B of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(B) Any of the following synthetic opiates, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers of them that are theoretically possible within the specific chemical designation:

(1) alfentanil;

(2) alphaprodine;

(3) anileridine;

(4) bezitramide;

(5) carfentanil;

(6) bulk dextropropoxyphene (non-dosage forms);

(7) dihydrocodeine;

(8) diphenoxylate;

(9) fentanyl;

(10) isomethadone;

(11) levomethorphan;

(12) levorphanol;

(13) metazocine;

(14) methadone;

(15) methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;

(16) moramide-intermediate, 2-methyl-3-morpholino-1, ~~1~~ 1-diphenylpropane-carboxylic acid;

(17) pethidine (meperidine);

(18) pethidine-intermediate-A, 4-cyano-l-methyl-4-phenylpiperidine;

(19) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

(20) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

(21) phenazocine;

(22) piminodine;

(23) racemethorphan;

(24) racemorphan;

(25) remifentanil;

(26) sufentanil;

(27) levo-alphacetylmethadol (other names: levo-alphaacetylmethadol, levomethadyl acetate, LAAM); and

(28) tapentadol."

Section 7. Item (C) of Appendix B of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(C) Material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system:

(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

(2) methamphetamine, its salts, isomers, and salts of its isomers;

(3) phenmetrazine and its salts;

(4) methylphenidate; and

(5) lisdexamfetamine, its salts, isomers, and salts of its isomers."

Section 8. Items (E) and (F) of Appendix B of Chapter 67, Title 9, Guam Code Annotated, are hereby *amended* to read:

"(E) Hallucinogenic substances.

(1) Nabilone [other names: (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one].

(F) Material, compound, mixture, or preparation containing any quantity of the following substances:

(1) Immediate precursor to amphetamine and methamphetamine: phenylacetone (other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone);

(2) Immediate precursors to phencyclidine (PCP):

(i) 1- phenylcyclohexylamine; and

(ii) 1-piperidinocyclohexanecarbonnitrile (PCC).

(3) Immediate precursor to fentanyl:

(i) 4-anilino-N-phenethyl-4-piperidine (ANPP)."

Section 9. Item (B) of Appendix C of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(B) A material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system:

(1) a compound, mixture, or preparation containing any of the following drugs or their salts and one or more other active medicinal ingredients not included in any schedule:

(A) amobarbital;

(B) secobarbital; and

(C) pentobarbital;

(2) any of the following drugs, or their salts, in suppository dosage form, approved by the Federal Food and Drug Administration for marketing only as a suppository:

(A) amobarbital;

(B) secobarbital, and

(C) pentobarbital;

(3) a substance containing any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid;

(4) chlorhexadol;

(5) embutramide;

(6) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug, and Cosmetic Act;

(7) ketamine, its salts, isomers, and salts of isomers [other names: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone];

(8) lysergic acid;

(9) lysergic acid amide;

(10) methyprylon;

(11) sulfondiethylmethane;

(12) sulfonethylmethane;

(13) sulfonmethane; and

(14) tiletamine and zolazepam, or any salt thereof [other names for a tiletamine-zolazepam combination product: Telazol; other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon]."

Section 10. Item C of Appendix C of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(C) Nalorphine;"

Section 11. Item (D) of Appendix C of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(D) Narcotic Drugs. (1) A material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(A) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(B) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(C) not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(D) not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active-nonnarcotic ingredients in recognized therapeutic amounts;

(E) not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(F) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(G) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; and

(H) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(2) A material, compound, mixture, or preparation containing any of the following narcotic drug and its salts:

(A) buprenorphine."

Section 12. Item (E) of Appendix C of Chapter 67 of Title 9 of the Guam Code Annotated is hereby *amended* to read:

"(E) Anabolic Steroids.

Any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:

(1) 3[beta], 17-dihydroxy-5a-androstane;

(2) 3[alpha], 17[beta]-dihydroxy-5a-androstane;

(3) 5[alpha]-androstan-3,17-dione;

(4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

(5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

(6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene;

(7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

(8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione;

(9) 4-androstenedione (androst-4-en-3,17-dione);

(10) 5-androstenedione (androst-5-en-3,17-dione);

(11) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3one);

(12) boldenone (17[beta]-hydroxyandrost-1,4,-diene-3-one);

(13) boldione (androsta-1,4-diene-3,17-dione);

(14) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

(15) chlorotestosterone (4-chlortestosterone),

(16) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

(17) dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy- 17[alpha]methyl-androst-1,4-dien-3-one);

(18) [Delta] 1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]- hydroxyl-5[alpha]-androst-1-en-3-one);

(19) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);

(20) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]- androstan-3-one);

(21) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);

(22) fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);

(23) formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);

(24) furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan);

(25) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;

(26) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one);

(27) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-4-en-3-one);

(28) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol) (a.k.a., madol);

(29) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3-one);

(30) mesterolone (1[alpha]methyl-17[beta]-hydroxy-[5[alpha]]-androstan-3-one);

(31) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);

(32) mathandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);

(33) methandranone;

(34) methandrostenolone;

(35) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);

(36) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane;

(37) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane;

(38) 17[alpha]-methyl-3[beta],17[beta],-dihydroxyandrost-4-ene;

(39) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);

(40) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);

(41) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9- 11-trien-3-one);

(42) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);

(43) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);

(44) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17- [alpha]-methyl-1-testosterone');

(45) nandrolone (17[beta]-hydroxyestr-4-en-3-one);

(46) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene);

(47) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene);

(48) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene);

(49) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene);

(50) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

(51) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(52) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(53) norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one);

(54) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);

(55) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);

(56) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);

(57) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-[5[alpha]]-androstan-3-one);

(58) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one;

(59) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3-one);

(60) stanolone;

(61) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-pyrazole);

(62) stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one);

(63) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

(64) testosterone (17[beta]-hydroxyandrost-4-en-3-one);

(65) tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11-trien-3-one);

(66) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); and

(67) Any salt, ester, or ether of a drug or substance described or listed in (1) through (66) above, if that salt, ester, or ether promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.

DPHSS may exempt by rule a compound, mixture, or preparation containing a stimulant or depressant substance listed in subsections A and B from the application of all or part of this Act, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for

abuse of the substances having a stimulant or depressant effect on the central nervous system."

Section 13. A new Item (F) is hereby *added* to Appendix C of Chapter 67, Title 9, Guam Code Annotated, to read:

"(F) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatine capsule in a U.S. Food and Drug Administration approved product [other names: (6a*R-trans*)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-dibenzo[*b,d*]pyran-1-ol] or (-)-delta-9-(*trans*)-tetrahydrocannabinol]."

Section 14. Item (B) of Appendix D of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(B) A material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(1) alprazolam;
(2) barbital;
(3) bromazepam;
(4) camazepam;
(5) chloral betaine;
(6) chloral hydrate;
(7) chlordiazepoxide;
(8) clobazam;
(9) clonazepam;
(10) clorazepate;
(11) clotiazepam;
(12) cloxazolam;
(13) delorazepam;

(14) diazepam;

(15) dichloraphenazone;

(16) estazolam;

(17) ethchlorvynol;

(18) ethinamate;

(19) ethyl loflazepate;

(20) fludiazepam;

(21) flunitrazepam;

(22) flurazepam;

(23) fospropofol;

(24) halazepam;

(25) haloxazolam;

(26) ketazolam;

(27) loprazolam;

(28) lorazepam;

(29) lormetazepam;

(30) mebutamate;

(31) medazepam;

(32) meprobamate;

(33) methohexital;

(34) methylphenobarbital (mephobarbital);

(35) midazolam;

(36) nimetazepam;

(37) nitrazepam;

(38) nordiazepam;

(39) oxazepam;

(40) oxazolam;

(41) paraldehyde;
(42) petrichloral;
(43) phenobarbital;
(44) pinazepam;
(45) prazepam;
(46) quazepam;
(47) temazepam;
(48) tetrazepam;
(49) triazolam;
(50) zaleplon;
(51) zolpidem; and
(52) zopiclone."

Section 15. Item (C) of Appendix D of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(C) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) fenfluramine."

Section 16. Item (D) of Appendix D of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(D) A material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:

(1) cathine ((+)-norpseudoephedrine);
(2) diethylpropion;

(3) fencamfamin;

(4) fenproporex;

(5) mazindol;

(6) mefenorex;

(7) modafinil;

(8) pemoline (including organometallic complexes and chelates thereof);

(9) phentermine;

(10) pipradrol;

(11) sibutramine; and

(12) SPA ((-)-1-dimethylamino-1,2-diphenylethane)."

Section 17. Item (A) of Appendix E of Chapter 67, Title 9, Guam Code Annotated, is hereby *amended* to read:

"(A) *Narcotic drugs*. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:"

Section 18. A new Item (D) of Appendix E of Chapter 67, Title 9, Guam Code Annotated, is hereby *added* to read:

"(D) A material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:

(1) lacosamide [(*R*)-2-acetoamido- *N* –benzyl-3-methoxy-propionamide]; and

(2) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]."

Section 19. A new §67.301(f) is hereby *added* to Article 3 of Chapter 67, Title 9, Guam Code Annotated, to read:

"(f) Guam Uniform Controlled Substances Act Review.

The Director may, in accordance with the Administrative Adjudication Law, conduct an annual review of the U.S. Drug Enforcement Administration Schedule Listing to determine whether the Guam Uniform Controlled Substances Act *shall* be revised in accordance."

Section 20. Effective Date. This Act *shall* take effect immediately upon enactment.